NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 245 filers reported holding NEKTAR THERAPEUTICS in Q1 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,646,000 | -13.8% | 76,249 | +31.3% | 0.05% | -8.0% |
| Q4 2018 | $1,909,000 | +23.6% | 58,085 | +128.6% | 0.05% | +56.2% |
| Q3 2018 | $1,545,000 | -54.2% | 25,407 | -82.3% | 0.03% | -61.0% |
| Q1 2017 | $3,372,000 | +47.1% | 143,675 | -23.1% | 0.08% | +1.2% |
| Q4 2016 | $2,293,000 | -73.8% | 186,906 | -63.3% | 0.08% | -70.1% |
| Q3 2016 | $8,759,000 | +80.1% | 509,810 | +49.2% | 0.27% | +69.4% |
| Q2 2016 | $4,864,000 | +31.7% | 341,794 | +27.2% | 0.16% | +50.9% |
| Q1 2016 | $3,694,000 | -4.5% | 268,689 | +17.7% | 0.11% | +16.5% |
| Q4 2015 | $3,870,000 | +615.3% | 228,306 | +362.4% | 0.09% | +435.3% |
| Q3 2015 | $541,000 | -12.5% | 49,373 | -9.4% | 0.02% | +6.2% |
| Q4 2013 | $618,000 | -15.5% | 54,478 | -22.1% | 0.02% | 0.0% |
| Q3 2013 | $731,000 | -56.9% | 69,930 | -52.4% | 0.02% | -65.2% |
| Q2 2013 | $1,696,000 | – | 146,840 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |